Role of homologous recombination/recombineering on human adenovirus genome engineering: Not the only but the most competent solution

Abstract

Adenoviruses typically cause mild illnesses, but severe diseases may occur primarily in immunodeficient individuals, particularly children. Recently, adenoviruses have garnered significant interest as a versatile tool in gene therapy, tumor treatment, and vaccine vector development. Over the past two decades, the advent of recombineering, a method based on homologous recombination, has notably enhanced the utility of adenoviral vectors in therapeutic applications. This review summarizes recent advancements in the use of human adenoviral vectors in medicine and discusses the pivotal role of recombineering in the development of these vectors. Additionally, it highlights the current achievements and potential future impact of therapeutic adenoviral vectors.

Keywords

Adenoviral vector / Gene therapy / Homologous recombination / Oncolytic virus / Vaccine vector

Declaration of Competing Interest

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:

Wenli Zhang reports financial support was provided by the Internal Research Funding from Witten Herdecke University (UWH). Anja Ehrhardt reports financial support was provided by the German Research Foundation (DFG). Wenli Zhang, Anja Ehrhardt has patent ADENOVIRAL VECTORS issued to GenArc Directions GmbH. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

CRediT authorship contribution statement

Lisa-Marie Dawson: Writing - original draft, Resources, Formal analysis, Writing - review & editing. Montaha Alshawabkeh: Writing - review & editing, Writing - original draft, Resources, Formal analysis. Katrin Schröer: Writing - original draft, Resources, Formal analysis, Writing - review & editing. Fatima Arakrak: Validation. Anja Ehrhardt: Writing - review & editing, Supervision, Project administration, Funding acquisition, Conceptualization. Wenli Zhang: Writing - review & editing, Writing - original draft, Supervision, Project administration, Conceptualization, Funding acquisition.

Acknowledgements

This work was in part funded by the DFG grant EH 192/5-3 (to AE), the internal grant program (project IFF 2024-91) of the Faculty of Health at Witten/Herdecke University (WZ and KS) and the PhD program at Witten/Herdecke University (LK).

References

[1] W.P. ROWE, R.J. HUEBNER, L.K. GILMORE, R.H. PARROTT, T.G. WARD, Isola- tion of a cytopathogenic agent from human adenoids undergoing spontaneous de- generation in tissue culture, Proc. Soc. Exp. Biol. Med. 84 (3) (1953) 570-573, doi:10.3181/00379727-84-20714.

[2] O.M. Al-Heeti, H.P. Cathro, M.G. Ison, Adenovirus infection and transplantation, Transplantation 106 (5) (2022) 920-927, doi:10.1097/TP.0000000000003988.

[3] J. Gu, Q.Q. Su, T.T. Zuo, Y.B. Chen, Adenovirus diseases: a systematic re- view and meta-analysis of 228 case reports, Infection 49 (1) (2021) 1-13, doi:10.1007/s15010-020-01484-7.

[4] T. Lion, Adenovirus infections in immunocompetent and immunocompromised pa- tients, Clin. Microbiol. Rev. 27 (3) (2014) 441-462, doi:10.1128/CMR.00116-13.

[5] K. Carr, Nobel goes to discoverers of ’split genes’, Nature 365 (6447) (1993) 597, doi:10.1038/365597a0.

[6] K. Garber, China approves world’s first oncolytic virus therapy for cancer treat- ment, J. Natl. Cancer Inst. 98 (5) (2006) 298-300, doi:10.1093/jnci/djj111.

[7] M. Liang, Oncorine, the world first oncolytic virus medicine and its update in China, Curr Cancer Drug Targets 18 (2) (2018) 171-176, doi:10.2174/1568009618666171129221503.

[8] V.P. Chavda, R. Bezbaruah, D. Valu, B. Patel, A. Kumar, S. Prasad, B.B. Kakoti, A. Kaushik, M. Jesawadawala, Adenoviral vector-based vaccine platform for COVID-19: current status, Vaccines (Basel) 11 (2) (2023), doi:10.3390/vac- cines11020432.

[9] C. Jacob-Dolan, D.H. Barouch, COVID-19 vaccines: adenoviral vectors, Annu. Rev. Med. 73 (2022) 41-54, doi:10.1146/annurev-med-012621-102252.

[10] Y. Zhang, J.P. Muyrers, G. Testa, A.F. Stewart, DNA cloning by homologous re- combination in Escherichia coli, Nat. Biotechnol. 18 (12) (2000) 1314-1317, doi:10.1038/82449.

[11] W. Zhang, A. Ehrhardt, Getting genetic access to natural adenovirus genomes to explore vector diversity, Virus Genes 53 (5) (2017) 675-683, doi:10.1007/s11262-017-1487-2.

[12] J. Fu, X. Bian, S. Hu, H. Wang, F. Huang, P.M. Seibert, A. Plaza, L. Xia, R. Müller, A.F. Stewart, Y. Zhang, Full-length RecE enhances linear-linear homologous recom- bination and facilitates direct cloning for bioprospecting, Nat. Biotechnol. 30 (5)(2012) 440-446, doi:10.1038/nbt.2183.

[13] W. Zhang, J. Fu, J. Liu, H. Wang, M. Schiwon, S. Janz, L. Schaffarczyk, L. von der Goltz, E. Ehrke-Schulz, J. Dörner, M. Solanki, P. Boehme, T. Bergmann, A. Lieber, C. Lauber, A. Dahl, A. Petzold, Y. Zhang, A.F. Stewart, A. Ehrhardt, An engineered virus library as a resource for the spectrum-wide exploration of virus and vector diversity, Cell Rep 19 (8) (2017) 1698-1709, doi:10.1016/j.celrep.2017.05.008.

[14] W. Zhang, K. Mese, S. Schellhorn, N. Bahlmann, N. Mach, O. Bunz, A. Dhingra, E. Hage, M.E. Lafon, H. Wodrich, A. Heim, A. Ehrhardt, High-throughput cloning and characterization of emerging adenovirus types 70, 73, 74, and 75, Int J Mol Sci 21 (17) (2020), doi:10.3390/ijms21176370.

[15] G.A. O’Hara, C.J.A. Duncan, K.J. Ewer, K.A. Collins, S.C. Elias, F.D. Halstead, A. L. Goodman, N.J. Edwards, A. Reyes-Sandoval, P. Bird, R. Rowland, S.H. Sheehy, I.D. Poulton, C. Hutchings, S. Todryk, L. Andrews, A. Folgori, E. Berrie, S. Moyle, A. Nicosia, S. Colloca, R. Cortese, L. Siani, A.M. Lawrie, S.C. Gilbert, A.V.S. Hill, Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector, J. Infect. Dis. 205 (5) (2012) 772-781, doi:10.1093/infdis/jir850.

[16] J.W. Shiver, T.M. Fu, L. Chen, D.R. Casimiro, M.E. Davies, R.K. Evans, Z.Q. Zhang, A.J. Simon, W.L. Trigona, S.A. Dubey, L. Huang, V.A. Harris, R.S. Long, X. Liang, L. Handt, W.A. Schleif, L. Zhu, D.C. Freed, N.V. Persaud, L. Guan, K.S. Punt, A. Tang, M. Chen, K.A. Wilson, K.B. Collins, G.J. Heidecker, V.R. Fernandez, H.C. Perry, J.G. Joyce, K.M. Grimm, J.C. Cook, P.M. Keller, D.S. Kresock, H. Mach, R.D. Troutman, L.A. Isopi, D.M. Williams, Z. Xu, K.E. Bohannon, D.B. Volkin, D.C. Montefiori, A. Miura, G.R. Krivulka, M.A. Lifton, M.J. Kuroda, J.E. Schmitz, N.L. Letvin, M.J. Caulfield, A.J. Bett, R. Youil, D.C. Kaslow, E.A. Emini, Replication- incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency- virus immunity, Nature 415 (6869) (2002) 331-335, doi:10.1038/415331a.

[17] N. Tatsis, H.C.J. Ertl, Adenoviruses as vaccine vectors, molecular therapy, J. Amer- ican Soci. Gene Ther. 10 (4) (2004) 616-629, doi:10.1016/j.ymthe.2004.07.013.

[18] G. Ghosh-Choudhury, Y. Haj-Ahmad, P. Brinkley, J. Rudy, F.L. Graham, Human adenovirus cloning vectors based on infectious bacterial plasmids, Gene 50 (1-3)(1986) 161-171, doi:10.1016/0378-1119(86)90321-5.

[19] C. Koger-Pease, D.J. Perera, M. Ndao, Recent advances in the development of adenovirus-vectored vaccines for parasitic infections, Pharmaceuticals (Basel) 16 (3) (2023), doi:10.3390/ph16030334.

[20] R.D. Antrobus, L. Coughlan, T.K. Berthoud, M.D. Dicks, A.V. Hill, T. Lambe, S. C. Gilbert, Clinical assessment of a novel recombinant simian adenovirus ChA- dOx1 as a vectored vaccine expressing conserved Influenza A antigens, Molecular therapy : the journal of the American Society of, Gene Ther. 22 (3) (2014) 668-674, doi:10.1038/mt.2013.284.

[21] A. Dalgleish, J. Stebbing, HIV-1 step study, Lancet 373 (9666) (2009) 805; author reply 806, doi:10.1016/S0140-6736(09)60470-0.

[22] D.H. Barouch, Novel adenovirus vector-based vaccines for HIV-1, Curr Opin HIV AIDS 5 (5) (2010) 386-390, doi:10.1097/COH.0b013e32833cfe4c.

[23] R.T. Schooley, J. Spritzler, H. Wang, M.M. Lederman, D. Havlir, D.R. Kuritzkes, R. Pollard, C. Battaglia, M. Robertson, D. Mehrotra, D. Casimiro, K. Cox, B. Schock, AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein, J. Infect. Dis. 202 (5) (2010) 705-716, doi:10.1086/655468.

[24] S. Rubinchik, J.S. Norris, J.Y. Dong, Construction, purification and characterization of adenovirus vectors expressing apoptosis-inducing transgenes, Meth. Enzymol. 346 (2002) 529-547, doi:10.1016/s0076-6879(02)46075-2.

[25] D. Wang, N.U. Raja, C.M. Trubey, L.Y. Juompan, M. Luo, J. Woraratanadharm, S.B. Deitz, H. Yu, B.M. Swain, K.M. Moore, W.D. Pratt, M.K. Hart, J.Y. Dong, De- velopment of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus, J. Virol. 80 (6)(2006) 2738-2746, doi:10.1128/JVI.80.6.2738-2746.2006.

[26] J.S. Richardson, M.K. Yao, K.N. Tran, M.A. Croyle, J.E. Strong, H. Feldmann, G.P. Kobinger, Enhanced protection against Ebola virus mediated by an im- proved adenovirus-based vaccine, PLoS ONE 4 (4) (2009) e5308, doi:10.1371/jour-nal.pone.0005308.

[27] W.D. Pratt, D. Wang, D.K. Nichols, M. Luo, J. Woraratanadharm, J.M. Dye, D. H. Holman, J.Y. Dong, Protection of nonhuman primates against two species of Ebola virus infection with a single complex adenovirus vector, Clin. Vaccine Immunol. 17 (4) (2010) 572-581, doi:10.1128/CVI.00467-09.

[28] J.H. Choi, K. Jonsson-Schmunk, X. Qiu, D.J. Shedlock, J. Strong, J.X. Xu, K. L. Michie, J. Audet, L. Fernando, M.J. Myers, D. Weiner, I. Bajrovic, L.Q. Tran, G. Wong, A. Bello, G.P. Kobinger, S.C. Schafer, M.A. Croyle, A Single Dose Res- piratory Recombinant Adenovirus-Based Vaccine Provides Long-Term Protection for Non-Human Primates from Lethal Ebola Infection, Mol. Pharm. 12 (8) (2015) 2712-2731, doi:10.1021/mp500646d.

[29] B.L. Bullard, B.N. Corder, D.N. Gordon, T.C. Pierson, E.A. Weaver, Characterization of a Species E Adenovirus Vector as a Zika virus vaccine, Sci Rep 10 (1) (2020) 3613, doi:10.1038/s41598-020-60238-5.

[30] L. Coughlan, E.J. Kremer, D.M. Shayakhmetov, Adenovirus-based vaccines-a plat- form for pandemic preparedness against emerging viral pathogens, Mol. Ther. 30 (5) (2022) 1822-1849, doi:10.1016/j.ymthe.2022.01.034.

[31] J.M. Powers, N.N. Haese, M. Denton, T. Ando, C. Kreklywich, K. Bonin, C.E. Stre- blow, N. Kreklywich, P. Smith, R. Broeckel, V. DeFilippis, T.E. Morrison, M. T. Heise, D.N. Streblow, Non-replicating adenovirus based Mayaro virus vaccine elicits protective immune responses and cross protects against other alphaviruses, PLoS Negl Trop Dis 15 (4) (2021) e0009308, doi:10.1371/journal.pntd.0009308.

[32] D.F. Havlicek, J.B. Rosenberg, B.P. De, M.J. Hicks, D. Sondhi, S.M. Kaminsky, R.G. Crystal, Cocaine vaccine dAd5GNE protects against moderate daily and high- dose "binge" cocaine use, PLoS ONE 15 (11) (2020) e0239780, doi:10.1371/jour- nal.pone.0239780.

[33] M.J. Hicks, B.P. De, J.B. Rosenberg, J.T. Davidson, A.Y. Moreno, K.D. Janda, S. Wee, G.F. Koob, N.R. Hackett, S.M. Kaminsky, S. Worgall, M. Toth, J.G. Mezey, R.G. Crystal, Cocaine analog coupled to disrupted adenovirus: a vaccine strategy to evoke high-titer immunity against addictive drugs, Mol. Ther. 19 (3) (2011) 612-619, doi:10.1038/mt.2010.280.

[34] G. Koob, M.J. Hicks, S. Wee, J.B. Rosenberg, B.P. De, S.M. Kaminsky, A. Moreno, K. D. Janda, R.G. Crystal, Anti-cocaine vaccine based on coupling a cocaine analog to a disrupted adenovirus, CNS Neurol Disord Drug Targ. 10 (8) (2011) 899-904, doi:10.2174/187152711799219334.

[35] S. Wee, M.J. Hicks, B.P. De, J.B. Rosenberg, A.Y. Moreno, S.M. Kamin- sky, K.D. Janda, R.G. Crystal, G.F. Koob, Novel cocaine vaccine linked to a disrupted adenovirus gene transfer vector blocks cocaine psychostimulant and reinforcing effects, Neuropsychopharmacology 37 (5) (2012) 1083-1091, doi:10.1038/npp.2011.200.

[36] A. Maoz, M.J. Hicks, S. Vallabhjosula, M. Synan, P.J. Kothari, J.P. Dyke, D.J. Bal- lon, S.M. Kaminsky, B.P. De, J.B. Rosenberg, D. Martinez, G.F. Koob, K.D. Janda, R.G. Crystal, Adenovirus capsid-based anti-cocaine vaccine prevents cocaine from binding to the nonhuman primate CNS dopamine transporter, Neuropsychophar- macology 38 (11) (2013) 2170-2178, doi:10.1038/npp.2013.114.

[37] M.J. Hicks, S.M. Kaminsky, B.P. De, J.B. Rosenberg, S.M. Evans, R.W. Foltin, D. M. Andrenyak, D.E. Moody, G.F. Koob, K.D. Janda, R.J. Ricart Arbona, M.L. Lep- herd, R.G. Crystal, Fate of systemically administered cocaine in nonhuman primates treated with the dAd5GNE anticocaine vaccine, Hum Gene Ther Clin Dev 25 (1)(2014) 40-49, doi:10.1089/humc.2013.231.

[38] X. Liu, L. Qu, X. Ye, C. Yi, X. Zheng, M. Hao, W. Su, Z. Yao, P. Chen, S. Zhang, Y. Feng, Q. Wang, Q. Yan, P. Li, H. Li, F. Li, W. Pan, X. Niu, R. Xu, L. Feng, L. Chen, Incorporation of NS1 and prM/M are important to confer effective protection of adenovirus-vectored Zika virus vaccine carrying E protein, NPJ vaccines 3 (2018) 29, doi:10.1038/s41541-018-0072-6.

[39] Y. Feng, C. Li, P. Hu, Q. Wang, X. Zheng, Y. Zhao, Y. Shi, S. Yang, C. Yi, Y. Feng, C. Wu, L. Qu, W. Xu, Y. Li, C. Sun, F.G. Gao, X. Xia, L. Feng, L. Chen, An aden- ovirus serotype 2-vectored ebolavirus vaccine generates robust antibody and cell- mediated immune responses in mice and rhesus macaques, Emerg. Microbes. Infect. 7 (1) (2018) 101, doi:10.1038/s41426-018-0102-5.

[40] B.A. Dudding, F.H. Top, R.M. Scott, P.K. Russell, E.L. Buescher, An analysis of hospi- talizations for acute respiratory disease in recruits immunized with adenovirus type 4 and type 7 vaccines, Am. J. Epidemiol. 95 (2) (1972) 140-147, doi:10.1093/ox- fordjournals.aje.a121378.

[41] J. Alexander, S. Ward, J. Mendy, D.J. Manayani, P. Farness, J.B. Avanzini, B. Guen- ther, F. Garduno, L. Jow, V. Snarsky, G. Ishioka, X. Dong, Lo Vang, M.J. Newman, T. Mayall, Pre-clinical evaluation of a replication-competent recombinant aden- ovirus serotype 4 vaccine expressing influenza H5 hemagglutinin, PLoS ONE 7 (2) (2012) e31177, doi:10.1371/journal.pone.0031177.

[42] S.M. Ghafoori, G.F. Petersen, D.G. Conrady, B.M. Calhoun, M.Z.Z. Stigliano, R.O. Baydo, R. Grice, J. Abendroth, D.D. Lorimer, T.E. Edwards, J.K. Forwood, Structural characterisation of hemagglutinin from seven Influenza A H1N1 strains reveal diversity in the C05 antibody recognition site, Sci Rep 13 (1) (2023) 6940, doi:10.1038/s41598-023-33529-w.

[43] D.C. Malherbe, J. Mendy, Lo Vang, P.T. Barnette, J. Reed, S.K. Lakhashe, J. Owuor, J.S. Gach, A.W. Legasse, M.K. Axthelm, C.C. LaBranche, D. Monte- fiori, D.N. Forthal, B. Park, J.M. Wilson, J.H. McLinden, J. Xiang, J.T. Stapleton, J.B. Sacha, B.F. Haynes, H.X. Liao, R.M. Ruprecht, J. Smith, M. Gurwith, N.L. Haig- wood, J. Alexander, Combination adenovirus and protein vaccines prevent infec- tion or reduce viral burden after heterologous Clade C simian-human immunodefi- ciency virus mucosal challenge, J. Virol. 92 (2) (2018), doi:10.1128/JVI.01092-17.

[44] B.L. Bullard, B.N. Corder, M.J. Gorman, M.S. Diamond, E.A. Weaver, Efficacy of a T cell-biased adenovirus vector as a zika virus vaccine, Sci Rep 8 (1) (2018) 18017, doi:10.1038/s41598-018-35755-z.

[45] B. Callendret, J. Vellinga, K. Wunderlich, A. Rodriguez, R. Steigerwald, U. Dirmeier, C. Cheminay, A. Volkmann, T. Brasel, R. Carrion, L.D. Giavedoni, J.L. Patter- son, C.E. Mire, T.W. Geisbert, J.W. Hooper, M. Weijtens, J. Hartkoorn-Pasma, J. Custers, M.Grazia Pau, H. Schuitemaker, R. Zahn, A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human pri- mates, PLoS ONE 13 (2) (2018) e0192312, doi:10.1371/journal.pone.0192312.

[46] R. Zahn, G. Gillisen, A. Roos, M. Koning, E. van der Helm, D. Spek, M. Wei- jtens, M.Grazia Pau, K. Radoš evi ć, G.J. Weverling, J. Custers, J. Vellinga, H. Schuitemaker, J. Goudsmit, A. Rodríguez, Ad35 and ad26 vaccine vectors in- duce potent and cross-reactive antibody and T-cell responses to multiple filovirusspecies, PLoS ONE 7 (12) (2012) e44115, doi:10.1371/journal.pone.0044115.

[47] D. Manno, A. Bangura, F. Baiden, A.B. Kamara, P. Ayieko, J. Kallon, J. Foster, M. Conteh, N.E. Connor, B. Koroma, Y. Njie, P. Borboh, B. Keshinro, B.J. Lawal, M.T. Kroma, G.T. Otieno, A.T. Deen, E.M.-L. Choi, A.D. Balami, A. Gaddah, C. McLean, K. Luhn, H.H. Adetola, G.F. Deen, M. Samai, B. Lowe, C. Robin- son, B. Leigh, B. Greenwood, D. Watson-Jones, Safety and immunogenicity of an Ad26.ZEBOV booster dose in children previously vaccinated with the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen: an open- label, non-randomised, phase 2 trial, Lancet Infect Dis 23 (3) (2023) 352-360, doi:10.1016/S1473-3099(22)00594-1.

[48] R.S. Freeman, S.J. Isenberg, The use of part-time occlusion for early onset unilateral exotropia, J Pediatr. Ophthalmol. Strabismus 26 (2) (1989) 94-96, doi:10.3928/0191-3913-19890301-14.

[49] L.R. Baden, S.R. Walsh, M.S. Seaman, R.P. Tucker, K.H. Krause, A. Patel, J.A. John- son, J. Kleinjan, K.E. Yanosick, J. Perry, E. Zablowsky, P. Abbink, L. Peter, M. J. Iampietro, A. Cheung, M.G. Pau, M. Weijtens, J. Goudsmit, E. Swann, M. Wolff, H. Loblein, R. Dolin, D.H. Barouch, First-in-human evaluation of the safety and im- munogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001), J. Infect. Dis. 207 (2) (2013) 240-247, doi:10.1093/infdis/jis670.

[50] L.R. Baden, D.J. Stieh, M. Sarnecki, S.R. Walsh, G.D. Tomaras, J.G. Kublin, M. J. McElrath, G. Alter, G. Ferrari, D. Montefiori, P. Mann, S. Nijs, K. Calle- waert, P. Goepfert, S. Edupuganti, E. Karita, J.P. Langedijk, F. Wegmann, L. Corey, M.G. Pau, D.H. Barouch, H. Schuitemaker, F. Tomaka, Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV- uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study, The lancet, HIV 7 (10) (2020) e688-e698,doi:10.1016/S2352-3018(20)30229-0.

[51] D.H. Barouch, F.L. Tomaka, F. Wegmann, D.J. Stieh, G. Alter, M.L. Robb, N. L. Michael, L. Peter, J.P. Nkolola, E.N. Borducchi, A. Chandrashekar, D. Jet- ton, K.E. Stephenson, W. Li, B. Korber, G.D. Tomaras, D.C. Montefiori, G. Gray, N. Frahm, M.J. McElrath, L. Baden, J. Johnson, J. Hutter, E. Swann, E. Karita, H. Kibuuka, J. Mpendo, N. Garrett, K. Mngadi, K. Chinyenze, F. Priddy, E. Lazarus, F. Laher, S. Nitayapan, P. Pitisuttithum, S. Bart, T. Campbell, R. Feldman, G. Lucksinger, C. Borremans, K. Callewaert, R. Roten, J. Sadoff, L. Scheppler, M. Weijtens, K. Feddes-de Boer, D. van Manen, J. Vreugdenhil, R. Zahn, L. Lavreys, S. Nijs, J. Tolboom, J. Hendriks, Z. Euler, M.G. Pau, H. Schuitemaker, Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo- controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19), Lancet 392 (10143) (2018) 232-243, doi:10.1016/S0140-6736(18)31364-3.

[52] N.C. Salisch, K.E. Stephenson, K. Williams, F. Cox, L. van der Fits, D. Heerwegh, C. Truyers, M.N. Habets, D.G. Kanjilal, R.A. Larocca, P. Abbink, J. Liu, L. Peter, C. Fierro, R.A. de La Barrera, K. Modjarrad, R.C. Zahn, J. Hendriks, C.P. Cahill, M. Leyssen, M. Douoguih, J. van Hoof, H. Schuitemaker, D.H. Barouch, A double- blind randomized, placebo-controlled phase 1 study of Ad26.ZIKV.001, an Ad26-vectored anti-zika virus vaccine, Ann. Intern. Med. 174 (5) (2021) 585-594, doi:10.7326/M20-5306.

[53] F. Cox, L. van der Fits, P. Abbink, R.A. Larocca, E. van Huizen, E. Saeland, J. Ver- hagen, R. Peterson, J. Tolboom, B. Kaufmann, H. Schuitemaker, D.H. Barouch, R. Zahn, Adenoviral vector type 26 encoding Zika virus (ZIKV) M-Env antigen induces humoral and cellular immune responses and protects mice and non- human primates against ZIKV challenge, PLoS ONE 13 (8) (2018) e0202820, doi:10.1371/journal.pone.0202820.

[54] P. Abbink, A.A.C. Lemckert, B.A. Ewald, D.M. Lynch, M. Denholtz, S. Smits, L. Holterman, I. Damen, R. Vogels, A.R. Thorner, K.L. O’Brien, A. Carville, K.G. Mansfield, J. Goudsmit, M.J.E. Havenga, D.H. Barouch, Comparative sero- prevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D, J. Virol. 81 (9) (2007) 4654-4663, doi:10.1128/JVI.02696-06.

[55] N.C. Salisch, A. Izquierdo Gil, D.N. Czapska-Casey, L. Vorthoren, J. Serroyen, J. Tol- boom, E. Saeland, H. Schuitemaker, R.C. Zahn, Adenovectors encoding RSV-F pro- tein induce durable and mucosal immunity in macaques after two intramuscular administrations, NPJ vaccines 4 (2019) 54, doi:10.1038/s41541-019-0150-4.

[56] M.N. Widjojoatmodjo, L. Bogaert, B. Meek, R. Zahn, J. Vellinga, J. Custers, J. Ser- royen, K. Radoš evi ć, H. Schuitemaker, Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion pro- tein induce protective immunity against RSV infection in cotton rats, Vaccine 33 (41) (2015) 5406-5414, doi:10.1016/j.vaccine.2015.08.056.

[57] A.R. Falsey, K. Williams, E. Gymnopoulou, S. Bart, J. Ervin, A.R. Bastian, J. Menten, E. de Paepe, S. Vandenberghe, E.K.H. Chan, J. Sadoff, M. Douoguih, B. Callen- dret, C.A. Comeaux, E. Heijnen, Efficacy and Safety of an Ad26.RSV. preF-RSV preF Protein Vaccine in Older Adults, New England j. med. 388 (7) (2023) 609-620, doi:10.1056/NEJMoa2207566.

[58] K. Williams, A.R. Bastian, R.A. Feldman, E. Omoruyi, E. de Paepe, J. Hen- driks, H. van Zeeburg, O. Godeaux, J.P.M. Langedijk, H. Schuitemaker, J. Sad- off, B. Callendret, Phase 1 safety and immunogenicity study of a respiratory syncytial virus vaccine with an adenovirus 26 vector encoding prefusion F (Ad26.RSV. preF) in adults aged ≥ 60 years, J. Infect. Dis. 222 (6) (2020) 979-988, doi:10.1093/infdis/jiaa193.

[59] S. Warming, N. Costantino, D.L. Court, N.A. Jenkins, N.G. Copeland, Simple and highly efficient BAC recombineering using galK selection, Nucleic Acids Res. 33 (4)(2005) e36, doi:10.1093/nar/gni035.

[60] K.M. Bricker, V. Obregon-Perko, F. Uddin, B. Williams, E.A. Uffman, C. Garrido, G.G. Fouda, R. Geleziunas, M. Robb, N. Michael, D.H. Barouch, A. Chahroudi, Therapeutic vaccination of SIV-infected, ART-treated infant rhesus macaques using Ad48/MVA in combination with TLR-7 stimulation, PLoS Pathog. 16 (10) (2020) e1008954, doi:10.1371/journal.ppat.1008954.

[61] R.A. Larocca, P. Abbink, J.P.S. Peron, P.M. d. A. Zanotto, M.J. Iampietro, A. Badamchi-Zadeh, M. Boyd, D. Ng’ang’a, M. Kirilova, R. Nityanandam, N.B. Mer- cado, Z. Li, E.T. Moseley, C.A. Bricault, E.N. Borducchi, P.B. Giglio, D. Jetton, G. Neubauer, J.P. Nkolola, L.F. Maxfield, R.A. de La Barrera, R.G. Jarman, K.H. Eck- els, N.L. Michael, S.J. Thomas, D.H. Barouch, Vaccine protection against Zika virus from Brazil, Nature 536 (7617) (2016) 474-478, doi:10.1038/nature18952.

[62] P. Abbink, R.A. Larocca, K. Visitsunthorn, M. Boyd, R.A. de La Barrera, G.D. Gro- mowski, M. Kirilova, R. Peterson, Z. Li, O. Nanayakkara, R. Nityanandam, N.B. Mer- cado, E.N. Borducchi, A. Chandrashekar, D. Jetton, S. Mojta, P. Gandhi, J. LeSuer, S. Khatiwada, M.G. Lewis, K. Modjarrad, R.G. Jarman, K.H. Eckels, S.J. Thomas, N.L. Michael, D.H. Barouch, Durability and correlates of vaccine protection against Zika virus in rhesus monkeys, Sci. Transl. Med. 9 (420) (2017), doi:10.1126/sci- translmed.aao4163.

[63] D.G. Gibson, L. Young, R.Y. Chuang, J.C. Venter, C.A. Hutchison, H.O. Smith, En- zymatic assembly of DNA molecules up to several hundred kilobases, Nat. Methods 6 (5) (2009) 343-345, doi:10.1038/nmeth.1318.

[64] D.K. Shay, R.C. Holman, R.D. Newman, L.L. Liu, J.W. Stout, L.J. Anderson, Bronchiolitis-associated hospitalizations among US children, 1980-1996, JAMA 282 (15) (1999) 1440-1446, doi:10.1001/jama.282.15.1440.

[65] J. Díez-Domingo, X. Sáez-Llorens, M.A. Rodriguez-Weber, C. Epalza, A. Chatterjee, C. H. Chiu, C.Y. Lin, A.A. Berry, F. Martinón-Torres, F. Baquero-Artigao, J.M. Lan- gley, J.T. Ramos Amador, J.B. Domachowske, L.M. Huang, N.C. Chiu, S. Espos- ito, P. Moris, T. Lien-Anh Nguyen, V. Nikic, W. Woo, Y. Zhou, I. Dieussaert, A. Leach, A. Gonzalez Lopez, N. Vanhoutte, Safety and immunogenicity of a ChAd155-vectored respiratory syncytial virus (RSV) vaccine in healthy RSV- seropositive children 12-23 months of age, J. Infect. Dis. 227 (11) (2023) 1293-1302, doi:10.1093/infdis/jiac481.

[66] B. Callendret, J. Vellinga, K. Wunderlich, A. Rodriguez, R. Steigerwald, U. Dirmeier, C. Cheminay, A. Volkmann, T. Brasel, R. Carrion, L.D. Giavedoni, J.L. Patterson, C.E. Mire, T.W. Geisbert, J.W. Hooper, M. Weijtens, J. Hartkoorn-Pasma, J. Custers, M.Grazia Pau, H. Schuitemaker, R. Zahn, Correction: a prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human pri- mates, PLoS ONE 13 (4) (2018) e0196546, doi:10.1371/journal.pone.0196546.

[67] R. Vogels, D. Zuijdgeest, R. van Rijnsoever, E. Hartkoorn, I. Damen, M.P. de Béthune, S. Kostense, G. Penders, N. Helmus, W. Koudstaal, M. Cecchini, A. Wetter- wald, M. Sprangers, A. Lemckert, O. Ophorst, B. Koel, M. van Meerendonk, P. Quax, L. Panitti, J. Grimbergen, A. Bout, J. Goudsmit, M. Havenga, Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient hu- man cell infection and bypass of preexisting adenovirus immunity, J. Virol. 77 (15) (2003) 8263-8271, doi:10.1128/jvi.77.15.8263-8271.2003.

[68] S.C. Elias, P. Choudhary, S.C. de Cassan, S. Biswas, K.A. Collins, F.D. Halstead, C. M. Bliss, K.J. Ewer, S.H. Hodgson, C.J.A. Duncan, A.V.S. Hill, S.J. Draper, Anal- ysis of human B-cell responses following ChAd63-MVA MSP1 and AMA1 immu- nization and controlled malaria infection, Immunology 141 (4) (2014) 628-644, doi:10.1111/imm.12226.

[69] S.H. Sheehy, C.J.A. Duncan, S.C. Elias, S. Biswas, K.A. Collins, G.A. O’Hara, F. D. Halstead, K.J. Ewer, T. Mahungu, A.J. Spencer, K. Miura, I.D. Poulton, M.D.J. Dicks, N.J. Edwards, E. Berrie, S. Moyle, S. Colloca, R. Cortese, K. Gantlett, C.A. Long, A.M. Lawrie, S.C. Gilbert, T. Doherty, A. Nicosia, A.V.S. Hill, S.J. Draper, Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors, PLoS ONE 7 (2) (2012) e31208, doi:10.1371/journal.pone.0031208.

[70] R. Morter, A.B. Tiono, I. Nébié, O. Hague, A. Ouedraogo, A. Diarra, N.K. Viebig, A. V.S. Hill, K.J. Ewer, S.B. Sirima, Impact of exposure to malaria and nutritional status on responses to the experimental malaria vaccine ChAd63 MVA ME-TRAP in 5-17 month-old children in Burkina Faso, Front Immunol 13 (2022) 1058227, doi:10.3389/fimmu.2022.1058227.

[71] J. Wang, Y. Li, N. Wang, J. Wu, X. Ye, Y. Jiang, L. Tang, Functions of exosomal non- coding RNAs to the infection with Mycobacterium tuberculosis, Front Immunol. 14 (2023) 1127214, doi:10.3389/fimmu.2023.1127214.

[72] J. Chakaya, E. Petersen, R. Nantanda, B.N. Mungai, G.B. Migliori, F. Amanullah, P. Lungu, F. Ntoumi, N. Kumarasamy, M. Maeurer, A. Zumla, The WHO Global Tuberculosis 2021 Report - not so good news and turning the tide back to End TB, Int. J. Infect. Dis. 124 (Suppl 1)(2022) S26-S29, doi:10.1016/j.ijid.2022.03.011.

[73] F. Cappuccini, E. Pollock, S. Stribbling, A.V.S. Hill, I. Redchenko, 5T 4 oncofoetal glycoprotein: an old target for a novel prostate cancer immunotherapy, Oncotarget 8 (29) (2017) 47474-47489, doi:10.18632/oncotarget.17666.

[74] M. McMahon, G. Asthagiri Arunkumar, W.C. Liu, D. Stadlbauer, R.A. Albrecht, V. Pavot, M. Aramouni, T. Lambe, S.C. Gilbert, F. Krammer, Vaccination with viral vectors expressing chimeric hemagglutinin, NP and M1 antigens pro- tects ferrets against influenza virus challenge, Front Immunol 10 (2019) 2005, doi:10.3389/fimmu.2019.02005.

[75] T. Donnison, J. McGregor, S. Chinnakannan, C. Hutchings, R.J. Center, P. Poum- bourios, P. Klenerman, H.E. Drummer, E. Barnes, A pan-genotype hepatitis C virus viral vector vaccine generates T cells and neutralizing antibodies in mice, Hepatol- ogy 76 (4) (2022) 1190-1202, doi:10.1002/hep.32470.

[76] P.M. Folegatti, K. Harrison, L. Preciado-Llanes, F.R. Lopez, M. Bittaye, Y.C. Kim, A. Flaxman, D. Bellamy, R. Makinson, J. Sheridan, S.R. Azar, R.K. Campos, M. Tilley, N. Tran, D. Jenkin, I. Poulton, A. Lawrie, R. Roberts, E. Berrie, S.L. Rossi, A. Hill, K.J. Ewer, A. Reyes-Sandoval, A single dose of ChAdOx1 Chik vaccine in- duces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial, Nat Commun 12 (1) (2021) 4636, doi:10.1038/s41467-021-24906-y.

[77] N. van Doremalen, T. Lambe, A. Spencer, S. Belij-Rammerstorfer, J.N. Pu- rushotham, J.R. Port, V.A. Avanzato, T. Bushmaker, A. Flaxman, M. Ulaszewska, F. Feldmann, E.R. Allen, H. Sharpe, J. Schulz, M. Holbrook, A. Okumura, K. Meade-White, L. Pérez-Pérez, N.J. Edwards, D. Wright, C. Bissett, C. Gilbride, B.N. Williamson, R. Rosenke, D. Long, A. Ishwarbhai, R. Kailath, L. Rose, S. Morris, C. Powers, J. Lovaglio, P.W. Hanley, D. Scott, G. Saturday, E. de Wit, S.C. Gilbert, V.J. Munster, ChAdOx 1 nCoV-19 vaccine prevents SARS- CoV-2 pneumonia in rhesus macaques, Nature 586 (7830) (2020) 578-582, doi:10.1038/s41586-020-2608-y.

[78] C. López-Camacho, P. Abbink, R.A. Larocca, W. Dejnirattisai, M. Boyd, A. Badamchi-Zadeh, Z.R. Wallace, J. Doig, R.S. Velazquez, R.D.L. Neto, D.F. Coelho, Y.C. Kim, C.L. Donald, A. Owsianka, G. de Lorenzo, A. Kohl, S.C. Gilbert, L. Dor- rell, J. Mongkolsapaya, A.H. Patel, G.R. Screaton, D.H. Barouch, A.V.S. Hill, A. Reyes-Sandoval, Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectors, Nat Commun 9 (1) (2018) 2441, doi:10.1038/s41467-018-04859-5.

[79] J.L. Hartley, G.F. Temple, M.A. Brasch, DNA cloning using in vitro site-specific re- combination, Genome Res. 10 (11) (2000) 1788-1795, doi:10.1101/gr.143000.

[80] C. López-Camacho, Y.C. Kim, J. Blight, M.Lazaro Moreli, E. Montoya-Diaz, J.T. Huiskonen, B.M. Kümmerer, A. Reyes-Sandoval, Assessment of immunogenic- ity and neutralisation efficacy of viral-vectored vaccines against chikungunya virus, Viruses 11 (4) (2019), doi:10.3390/v11040322.

[81] M.D.J. Dicks, A.J. Spencer, N.J. Edwards, G. Wadell, K. Bojang, S.C. Gilbert, A. V.S. Hill, M.G. Cottingham, A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and com- parative immunogenicity, PLoS ONE 7 (7) (2012) e40385, doi:10.1371/jour- nal.pone.0040385.

[82] X. Liang, L. Peng, C.H. Baek, F. Katzen, Single step BP/LR combined Gateway re- actions, BioTechniques 55 (5) (2013) 265-268, doi:10.2144/000114101.

[83] R. Lu, X. Zhao, J. Li, P. Niu, B. Yang, H. Wu, W. Wang, H. Song, B. Huang, N. Zhu, Y. Bi, X. Ma, F. Zhan, L. Wang, T. Hu, H. Zhou, Z. Hu, W. Zhou, L. Zhao, J. Chen, Y. Meng, J. Wang, Y. Lin, J. Yuan, Z. Xie, J. Ma, W.J. Liu, D. Wang, W. Xu, E.C. Holmes, G.F. Gao, G. Wu, W. Chen, W. Shi, W. Tan, Ge- nomic characterisation and epidemiology of 2019 novel coronavirus: implica- tions for virus origins and receptor binding, Lancet 395(10224)(2020) 565-574, doi:10.1016/S0140-6736(20)30251-8.

[84] D.Y. Logunov, I.V. Dolzhikova, O.V. Zubkova, A.I. Tukhvatullin, D.V. Shcheblyakov, A.S. Dzharullaeva, D.M. Grousova, A.S. Erokhova, A.V. Kovyr- shina, A.G. Botikov, F.M. Izhaeva, O. Popova, T.A. Ozharovskaya, I.B. Esmagambe- tov, I.A. Favorskaya, D.I. Zrelkin, D.V. Voronina, D.N. Shcherbinin, A.S. Semikhin, Y.V. Simakova, E.A. Tokarskaya, N.L. Lubenets, D.A. Egorova, M.M. Shmarov, N.A. Nikitenko, L.F. Morozova, E.A. Smolyarchuk, E.V. Kryukov, V.F. Babira, S.V. Borisevich, B.S. Naroditsky, A.L. Gintsburg, Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia, Lancet 396 (10255) (2020) 887-897, doi:10.1016/S0140-6736(20)31866-3.

[85] M.G. Abrignani, A. Murrone, L. de Luca, L. Roncon, A. Di Lenarda, S. Valente, P. Cal- darola, C. Riccio, F. Oliva, M.M. Gulizia, D. Gabrielli, F. Colivicchi, B.O.T.W.G.O.A.-C.-V.O.T.A.N.M.C.O.A. On. COVID-19, vaccines, and thrombotic events: a narrative review, J Clin Med 11 (4) (2022), doi:10.3390/jcm11040948.

[86] Y. Zhang, L. Feng, L. Li, D. Wang, C. Li, C. Sun, P. Li, X. Zheng, Y. Liu, W. Yang, X. Niu, N. Zhong, L. Chen, Effects of the fusion design and im- munization route on the immunogenicity of Ag85A-Mtb32 in adenoviral vec- tored tuberculosis vaccine, Hum Vaccin Immunother 11 (7) (2015) 1803-1813, doi:10.1080/21645515.2015.1042193.

[87] L. Xiao, D. Wang, C. Sun, P. Li, Y. Jin, L. Feng, L. Chen, Enhancement of SIV-specific cell mediated immune responses by co-administration of soluble PD-1 and Tim-3 as molecular adjuvants in mice, Hum Vaccin Immunother 10 (3) (2014) 724-733, doi:10.4161/hv.27340.

[88] K. Matsuda, S.A. Migueles, J. Huang, L. Bolkhovitinov, S. Stuccio, T. Griesman, A.A. Pullano, B.H. Kang, E. Ishida, M. Zimmerman, N. Kashyap, K.M. Martins, D. Stadlbauer, J. Pederson, A. Patamawenu, N. Wright, T. Shofner, S. Evans, C.J. Liang, J. Candia, A. Biancotto, G. Fantoni, A. Poole, J. Smith, J. Alexan- der, M. Gurwith, F. Krammer, M. Connors, A replication-competent adenovirus- vectored influenza vaccine induces durable systemic and mucosal immunity, J. Clin. Invest. 131 (5) (2021), doi:10.1172/JCI140794.

[89] C. Chartier, E. Degryse, M. Gantzer, A. Dieterle, A. Pavirani, M. Mehtali, Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli, J. Virol. 70 (7) (1996) 4805-4810, doi:10.1128/JVI.70.7.4805-4810.1996.

[90] A.-M.C. Andersson, M. Resende, A. Salanti, M.A. Nielsen, P.J. Holst, Novel adenovirus encoded virus-like particles displaying the placental malaria associated VAR2CSA antigen, Vaccine 35 (8) (2017) 1140-1147, doi:10.1016/j.vaccine.2017.01.016.

[91] L. Cao, W. Wang, W. Sun, J. Zhang, J. Han, C. Xie, Z. Ha, Y. Xie, H. Zhang, N. Jin, H. Lu, Construction and evaluation of recombinant adenovirus candidate vaccines for chikungunya virus, Viruses 14 (8) (2022), doi:10.3390/v14081779.

[92] E. Kim, G. Erdos, S. Huang, T. Kenniston, L.D. Falo, A. Gambotto, Preventative Vaccines for Zika Virus Outbreak: preliminary Evaluation, EBioMedicine 13 (2016) 315-320, doi:10.1016/j.ebiom.2016.09.028.

[93] D. Lioznov, I. Amosova, S.A. Sheetikov, K.V. Zornikova, Y. Serdyuk, G.A. Efi- mov, M. Tsyferov, M. Khmelevskii, A. Afanasiev, N. Khomyakova, D. Zubkov, A. Tikhonov, T. Zhu, L. Barreto, V. Dzutseva, Immunogenicity and safety of a re- combinant adenovirus type-5 COVID-19 vaccine in adults: data from a randomised, double-blind, placebo-controlled, single-dose, phase 3 trial in Russia, PLoS ONE 18 (3) (2023) e0278878, doi:10.1371/journal.pone.0278878.

[94] S. Wu, J. Huang, Z. Zhang, J. Wu, J. Zhang, H. Hu, T. Zhu, J. Zhang, L. Luo, P. Fan, B. Wang, C. Chen, Y. Chen, X. Song, Y. Wang, W. Si, T. Sun, X. Wang, L. Hou, W. Chen, Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial, Lancet Infect Dis 21 (12)(2021) 1654-1664, doi:10.1016/S1473-3099(21)00396-0.

[95] L. Feng, Q. Wang, C. Shan, C. Yang, Y. Feng, J. Wu, X. Liu, Y. Zhou, R. Jiang, P. Hu, X. Liu, F. Zhang, P. Li, X. Niu, Y. Liu, X. Zheng, J. Luo, J. Sun, Y. Gu, B. Liu, Y. Xu, C. Li, W. Pan, J. Zhao, C. Ke, X. Chen, T. Xu, N. Zhong, S. Guan, Z. Yuan, L. Chen, An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaques, Nat Commun 11 (1) (2020) 4207, doi:10.1038/s41467-020-18077-5.

[96] K. Hardt an Vandebosch, J. Sadoff M. Le Gars C. Truyers D. Lowson I. van Dromme J. Vingerhoets T. Kamphuis G. Scheper J. Ruiz-Guiñazú S.N. Faust C. D. Spinner H. Schuitemaker J. van Hoof M. Douoguih F. Struyf, Effi- cacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vac- cine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet Infect Dis 22 (12) (2022) 1703-1715, doi:10.1016/S1473-3099(22)00506-0.

[97] L.R. Baden, E. Karita, G. Mutua, L.G. Bekker, G. Gray, L. Page-Shipp, S.R. Walsh, J. Nyombayire, O. Anzala, S. Roux, F. Laher, C. Innes, M.S. Seaman, Y.Z. Cohen, L. Peter, N. Frahm, M.J. McElrath, P. Hayes, E. Swann, N. Grunenberg, M. Grazia-Pau, M. Weijtens, J. Sadoff, L. Dally, A. Lombardo, J. Gilmour, J. Cox, R. Dolin, P. Fast, D.H. Barouch, D.S. Laufer, Assessment of the safety and immunogenicity of 2 novel vaccine platforms for HIV-1 prevention: a randomized trial, Ann. Intern. Med. 164 (5) (2016) 313-322, doi:10.7326/M15-0880.

[98] R. Vogels, D. Zuijdgeest, M. van Meerendonk, A. Companjen, G. Gillissen, J. Sijtsma, I. Melis, L. Holterman, K. Radosevic, J. Goudsmit, M.J.E. Havenga, High-level expression from two independent expression cassettes in replication- incompetent adenovirus type 35 vector, J. Gen. Virol. 88 (Pt 11) (2007) 2915-2924, doi:10.1099/vir.0.83119-0.

[99] N.C. Salisch, M. Vujadinovic, E. van der Helm, D. Spek, L. Vorthoren, J. Serroyen, H. Kuipers, H. Schuitemaker, R. Zahn, J. Custers, J. Vellinga, Antigen capsid-display on human adenovirus 35 via pIX fusion is a potent vaccine platform, PLoS ONE 12 (3) (2017) e0174728, doi:10.1371/journal.pone.0174728.

[100] R.N. van Zyl-Smit, A. Esmail, M.E. Bateman, R. Dawson, J. Goldin, E. van Rikxoort, M. Douoguih, M.G. Pau, J.C. Sadoff, J.B. McClain, M.A. Snowden, J. Benko, D.A. Hokey, K.T. Rutkowski, A. Graves, B. Shepherd, S. Ishmukhame- dov, B.M.N. Kagina, B. Abel, W.A. Hanekom, T.J. Scriba, E.D. Bateman, Safety and immunogenicity of adenovirus 35 tuberculosis vaccine candidate in adults with active or previous tuberculosis. A randomized trial, Am. J. Respir. Crit. Care Med. 195 (9) (2017) 1171-1180, doi:10.1164/rccm.201603-0654OC.

[101] A.L. Farrow, B.J. Peng, L. Gu, A. Krendelchtchikov, Q.L. Matthews, A novel vaccine approach for chagas disease using rare adenovirus serotype 48 vectors, Viruses 8 (3) (2016) 78, doi:10.3390/v8030078.

[102] A. von Delft, T.A. Donnison, J. Lourenço, C. Hutchings, C.E. Mullarkey, A. Brown, O.G. Pybus, P. Klenerman, S. Chinnakannan, E. Barnes, The generation of a simian adenoviral vectored HCV vaccine encoding genetically conserved gene segments to target multiple HCV genotypes, Vaccine 36 (2) (2018) 313-321, doi:10.1016/j.vaccine.2017.10.079.

[103] G. Di Lullo, E. Soprana, M. Panigada, A. Palini, A. Agresti, C. Comunian, A. Milani, I. Capua, V. Erfle, A.G. Siccardi, The combination of marker gene swapping and fluorescence-activated cell sorting improves the efficiency of recombinant modified vaccinia virus Ankara vaccine production for human use, J. Virol. Methods 163 (2)(2010) 195-204, doi:10.1016/j.jviromet.2009.09.016.

[104] D.A. Stanley, A.N. Honko, C. Asiedu, J.C. Trefry, A.W. Lau-Kilby, J.C. Johnson, L. Hensley, V. Ammendola, A. Abbate, F. Grazioli, K.E. Foulds, C. Cheng, L. Wang, M.M. Donaldson, S. Colloca, A. Folgori, M. Roederer, G.J. Nabel, J. Mascola, A. Nicosia, R. Cortese, R.A. Koup, N.J. Sullivan, Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge, Nat. Med. 20 (10) (2014) 1126-1129, doi:10.1038/nm.3702.

[105] J.E. Ledgerwood, A.D. DeZure, D.A. Stanley, E.E. Coates, L. Novik, M.E. Enama, N. M. Berkowitz, Z. Hu, G. Joshi, A. Ploquin, S. Sitar, I.J. Gordon, S.A. Plum- mer, L.A. Holman, C.S. Hendel, G. Yamshchikov, F. Roman, A. Nicosia, S. Col- loca, R. Cortese, R.T. Bailer, R.M. Schwartz, M. Roederer, J.R. Mascola, R.A. Koup, N.J. Sullivan, B.S. Graham, Chimpanzee adenovirus vector ebola vaccine, New Eng- land j. med. 376 (10) (2017) 928-938, doi:10.1056/NEJMoa1410863.

[106] K. Xu, Y. Song, L. Dai, Y. Zhang, X. Lu, Y. Xie, H. Zhang, T. Cheng, Q. Wang, Q. Huang, Y. Bi, W.J. Liu, W. Liu, X. Li, C. Qin, Y. Shi, J. Yan, D. Zhou, G.F. Gao, Recombinant chimpanzee adenovirus vaccine AdC7-M/E protects against zika virus infection and testis damage, J. Virol. 92 (6) (2018), doi:10.1128/JVI.01722-17.

[107] D. Zhou, X. Zhou, A. Bian, H. Li, H. Chen, J.C. Small, Y. Li, W. Giles-Davis, Z. Xiang, H. C.J. Ertl, An efficient method of directly cloning chimpanzee adenovirus as a vaccine vector, Nat Protoc 5 (11) (2010) 1775-1785, doi:10.1038/nprot.2010.134.

[108] S.H. Sheehy, C.J.A. Duncan, S.C. Elias, K.A. Collins, K.J. Ewer, A.J. Spencer, A.R. Williams, F.D. Halstead, S.E. Moretz, K. Miura, C. Epp, M.D.J. Dicks, I.D. Poul- ton, A.M. Lawrie, E. Berrie, S. Moyle, C.A. Long, S. Colloca, R. Cortese, S.C. Gilbert, A. Nicosia, A.V.S. Hill, S.J. Draper, Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors, Mol. Ther. 19 (12) (2011) 2269-2276, doi:10.1038/mt.2011.176.

[109] S.H. Sheehy, C.J.A. Duncan, S.C. Elias, P. Choudhary, S. Biswas, F.D. Halstead, K.A. Collins, N.J. Edwards, A.D. Douglas, N.A. Anagnostou, K.J. Ewer, T. Havelock, T. Mahungu, C.M. Bliss, K. Miura, I.D. Poulton, P.J. Lillie, R.D. Antrobus, E. Berrie, S. Moyle, K. Gantlett, S. Colloca, R. Cortese, C.A. Long, R.E. Sinden, S.C. Gilbert, A.M. Lawrie, T. Doherty, S.N. Faust, A. Nicosia, A.V.S. Hill, S.J. Draper, ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans, Mol. Ther. 20 (12) (2012) 2355-2368, doi:10.1038/mt.2012.223.

[110] M.M. Hou, J.R. Barrett, Y. Themistocleous, T.A. Rawlinson, A. Diouf, F.J. Martinez, C. M. Nielsen, A.M. Lias, L.D.W. King, N.J. Edwards, N.M. Greenwood, L. King- ham, I.D. Poulton, B. Khozoee, C. Goh, D.J. Mac Lochlainn, J. Salkeld, M. Guilotte- Blisnick, C. Huon, F. Mohring, J.M. Reimer, V.S. Chauhan, P. Mukherjee, S. Biswas, I.J. Taylor, A.M. Lawrie, J.S. Cho, F.L. Nugent, C.A. Long, R.W. Moon, K. Miura, S.E. Silk, C.E. Chitnis, A.M. Minassian, S.J. Draper, Impact of a blood-stage vac- cine on Plasmodium vivax malaria, medRxiv, Preprint Server Health Sci. (2022), doi:10.1101/2022.05.27.22275375.

[111] A. Maroof, N. Brown, B. Smith, M.R. Hodgkinson, A. Maxwell, F.O. Losch, U. Fritz, P. Walden, C.N.J. Lacey, D.F. Smith, T. Aebischer, P.M. Kaye, Thera- peutic vaccination with recombinant adenovirus reduces splenic parasite burden in experimental visceral leishmaniasis, J. Infect. Dis. 205 (5) (2012) 853-863, doi:10.1093/infdis/jir842.

[112] M. Osman, A. Mistry, A. Keding, R. Gabe, E. Cook, S. Forrester, R. Wiggins, S. Di Marco, S. Colloca, L. Siani, R. Cortese, D.F. Smith, T. Aebischer, P.M. Kaye, C.J. Lacey, A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: first-in-human trial of ChAd63-KH, PLoS Negl Trop Dis 11 (5) (2017) e0005527, doi:10.1371/journal.pntd.0005527.

[113] B.M. Younis, M. Osman, E.A.G. Khalil, F. Santoro, S. Furini, R. Wiggins, A. Keding, M. Carraro, A.E.A. Musa, M.A.A. Abdarahaman, L. Mandefield, M. Bland, T. Aebischer, R. Gabe, A.M. Layton, C.J.N. Lacey, P.M. Kaye, A.M. Musa, Safety and immunogenicity of ChAd63-KH vaccine in post-kala-azar dermal leishmaniasis patients in Sudan, Mol. Ther. 29 (7) (2021) 2366-2377, doi:10.1016/j.ymthe.2021.03.020.

[114] P. Cicconi, C. Jones, E. Sarkar, L. Silva-Reyes, P. Klenerman, C. de Lara, C. Hutch- ings, P. Moris, M. Janssens, L.A. Fissette, M. Picciolato, A. Leach, A. Gonzalez-Lopez, I. Dieussaert, M.D. Snape, First-in-Human Randomized Study to Assess the Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus (RSV) Vaccine Based on Chimpanzee-Adenovirus-155 Viral Vector-Expressing RSV Fu- sion, Official Publicat. Infectious Dis. Soc. America 70 (10) (2020) 2073-2081, doi:10.1093/cid/ciz653.

[115] J. Luo, Z.L. Deng, X. Luo, N. Tang, W.X. Song, J. Chen, K.A. Sharff, H.H. Luu, R. C. Haydon, K.W. Kinzler, B. Vogelstein, T.C. He, A protocol for rapid generation of recombinant adenoviruses using the AdEasy system, Nat Protoc 2 (5) (2007) 1236-1247, doi:10.1038/nprot.2007.135.

[116] S.E. Raper, M. Yudkoff, N. Chirmule, G.P. Gao, F. Nunes, Z.J. Haskal, E.E. Furth, K.J. Propert, M.B. Robinson, S. Magosin, H. Simoes, L. Speicher, J. Hughes, J. Tazelaar, N.A. Wivel, J.M. Wilson, M.L. Batshaw, A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial or- nithine transcarbamylase deficiency, Hum. Gene Ther. 13 (1) (2002) 163-175, doi:10.1089/10430340152712719.

[117] R.J. Parks, L. Chen, M. Anton, U. Sankar, M.A. Rudnicki, F.L. Graham, A helper- dependent adenovirus vector system: removal of helper virus by Cre-mediated ex- cision of the viral packaging signal, Proc. Natl. Acad. Sci. U.S.A. 93 (24) (1996) 13565-13570, doi:10.1073/pnas.93.24.13565.

[118] L. Jager, M.A. Hausl, C. Rauschhuber, N.M. Wolf, M.A. Kay, A. Ehrhardt, A rapid protocol for construction and production of high-capacity adenoviral vectors, Nat Protoc 4 (4) (2009) 547-564, doi:10.1038/nprot.2009.4.

[119] P. Ng, C. Evelegh, D. Cummings, F.L. Graham, Cre levels limit packaging signal excision efficiency in the Cre/loxP helper-dependent adenoviral vector system, J. Virol. 76 (9) (2002) 4181-4189, doi:10.1128/jvi.76.9.4181-4189.2002.

[120] P. Umaña, C.A. Gerdes, D. Stone, J.R. Davis, D. Ward, M.G. Castro, P.R. Lowen- stein, Efficient FLPe recombinase enables scalable production of helper-dependent adenoviral vectors with negligible helper-virus contamination, Nat. Biotechnol. 19 (6) (2001) 582-585, doi:10.1038/89349.

[121] Y. Yang, H.C. Ertl, J.M. Wilson, MHC class I-restricted cytotoxic T lym- phocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses, Immunity 1 (5) (1994) 433-442, doi:10.1016/1074-7613(94)90074-4.

[122] D. Lee, J. Liu, H.J. Junn, E.J. Lee, K.S. Jeong, D.W. Seol, No more helper aden- ovirus: production of gutless adenovirus (GLAd) free of adenovirus and replication- competent adenovirus (RCA) contaminants, Exp. Mol. Med. 51 (10) (2019) 1-18, doi:10.1038/s12276-019-0334-z.

[123] R. Alemany, Y. Dai, Y.C. Lou, E. Sethi, E. Prokopenko, S.F. Josephs, W.W. Zhang, Complementation of helper-dependent adenoviral vectors: size effects and titer fluctuations, J. Virol. Methods 68 (2) (1997) 147-159.

[124] C. Peixoto, T.B. Ferreira, M.F.Q. Sousa, M.J.T. Carrondo, P.M. Alves, Towards pu- rification of adenoviral vectors based on membrane technology, Biotechnol. Prog. 24 (6) (2008) 1290-1296, doi:10.1002/btpr.25.

[125] R.F. Kratzer, F. Kreppel, Production, Purification, and Titration of First-Generation Adenovirus Vectors, Methods Mol. Biol. 1654 (2017) 377-388, doi:10.1007/978-1-4939-7231-9_28.

[126] N. Mittereder, K.L. March, B.C. Trapnell, Evaluation of the concentration and bioac- tivity of adenovirus vectors for gene therapy, J. Virol. 70 (11) (1996) 7498-7509, doi:10.1128/JVI.70.11.7498-7509.1996.

[127] J.A. Sweeney, J.P. Hennessey, Evaluation of accuracy and precision of adenovirus absorptivity at 260nm under conditions of complete DNA disruption, Virology 295 (2) (2002) 284-288, doi:10.1006/viro.2002.1406.

[128] M. Puntel, J.F. Curtin, J.M. Zirger, A.K.M. Muhammad, W. Xiong, C. Liu, J. Hu, K. M. Kroeger, P. Czer, S. Sciascia, S. Mondkar, P.R. Lowenstein, M.G. Castro, Quan- tification of high-capacity helper-dependent adenoviral vector genomes in vitro and in vivo, using quantitative TaqMan real-time polymerase chain reaction, Hum. Gene Ther. 17 (5) (2006) 531-544, doi:10.1089/hum.2006.17.531.

[129] E. Bilkova, J. Forstova, L. Abrahamyan, Coat as a dagger: the use of capsid proteins to perforate membranes during non-enveloped DNA viruses trafficking, Viruses 6 (7) (2014) 2899-2937, doi:10.3390/v6072899.

[130] M. Suzuki, V. Cerullo, T.K. Bertin, R. Cela, C. Clarke, M. Guenther, N. Brunetti-Pierri, B. Lee, MyD88-dependent silencing of transgene expression during the in- nate and adaptive immune response to helper-dependent adenovirus, Hum. Gene Ther. 21 (3) (2010) 325-336, doi:10.1089/hum.2009.155.

[131] A.J. Ullman, N.C. Reich, P. Hearing, Adenovirus E4 ORF3 protein inhibits the interferon-mediated antiviral response, J. Virol. 81 (9) (2007) 4744-4752, doi:10.1128/JVI.02385-06.

[132] A. Ehrhardt, H. Xu, M.A. Kay, Episomal persistence o (2) (f recombinant adenoviral vector genomes during the cell cycle in vivo, J. Virol. 77 (13) (2003) 7689-7695, doi:10.1128/jvi.77.13.7689-7695.2003.

[133] C.M. Wong, E.R. McFall, J.K. Burns, R.J. Parks, The role of chromatin in adenoviral vector function, Viruses 5 (6) (2013) 1500-1515, doi:10.3390/v5061500.

[134] P.J. Ross, M.A. Kennedy, R.J. Parks, Host cell detection of noncoding stuffer DNA contained in helper-dependent adenovirus vectors leads to epigenetic re- pression of tran (2) (sgene expression, J. Virol. 83 (17) (2009) 8409-8417, doi:10.1128/JVI.00796-09.

[135] N. Brunetti-Pierri, T. Ng, D. Iannitti, W. Cioffi, G. Stapleton, M. Law, J. Breinholt, D. Palmer, N. Grove, K. Rice, C. Bauer, M. Finegold, A. Beaudet, C. Mullins, P. Ng, Transgene expression up to 7 years in nonhuman primates following hepatic trans- duction with helper-dependent adenoviral vectors, Hum. Gene Ther. 24 (8) (2013) 761-765, doi:10.1089/hum.2013.071.

[136] C. Balagué, J. Zhou, Y. Dai, R. Alemany, S.F. Josephs, G. Andreason, M. Hariharan, E. Sethi, E. Prokopenko, H.Y. Jan, Y.C. Lou, D. Hubert-Leslie, L. Ruiz, W.W. Zhang, Sustained high-level expression of full-length human factor VIII and restoration of clotting activity in hemophilic mice using a minimal adenovirus vector, Blood 95 (3) (2000) 820-828.

[137] W.W. Zhang, S.F. Josephs, J. Zhou, X. Fang, R. Alemany, C. Balagué, Y. Dai, D. Ayares, E. Prokopenko, Y.C. Lou, E. Sethi, D. Hubert-Leslie, M. Kennedy, L. Ruiz, S. Rockow-Magnone, Development and application of a minimal-adenoviral vec- tor system for gene therapy of hemophilia A, Thromb. Haemost. 82 (2) (1999) 562-571.

[138] S. Kochanek, P.R. Clemens, K. Mitani, H.H. Chen, S. Chan, C.T. Caskey, A new adenoviral vector: replacement of all viral coding sequences with 28kb of DNA independently expressing both full-length dystrophin and beta-galactosidase, Proc. Natl. Acad. Sci. U.S.A. 93 (12) (1996) 5731-5736, doi:10.1073/pnas.93.12.5731.

[139] A. Ehrhardt, M.A. Kay, A new adenoviral helper-dependent vector results in long- term therapeutic levels of human coagulation factor IX at low doses in vivo, Blood 99 (11) (2002) 3923-3930, doi:10.1182/blood.v99.11.3923.

[140] A. Ehrhardt, H. Xu, A.M. Dillow, D.A. Bellinger, T.C. Nichols, M.A. Kay, A gene- deleted adenoviral vector results in phenotypic correction of canine hemophilia B without liver toxicity or thrombocytopenia, Blood 102 (7) (2003) 2403-2411, doi:10.1182/blood-2003-01-0314.

[141] N. Brunetti-Pierri, T.C. Nichols, S. McCorquodale, E. Merricks, D.J. Palmer, A. L. Beaudet, P. Ng, Sustained phenotypic correction of canine hemophilia B after systemic administration of helper-dependent adenoviral vector, Hum. Gene Ther. 16 (7) (2005) 811-820, doi:10.1089/hum.2005.16.811.

[142] N. Morral, W. O’Neal, K. Rice, M. Leland, J. Kaplan, P.A. Piedra, H. Zhou, R.J. Parks, R. Velji, E. Aguilar-Córdova, S. Wadsworth, F.L. Graham, S. Kochanek, K. D. Carey, A.L. Beaudet, Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons,Proc. Natl. Acad. Sci. U.S.A. 96 (22) (1999) 12816-12821, doi:10.1073/pnas.96.22.12816.

[143] N. Brunetti-Pierri, G.E. Stapleton, M. Law, J. Breinholt, D.J. Palmer, Y. Zuo, N. C. Grove, M.J. Finegold, K. Rice, A.L. Beaudet, C.E. Mullins, P. Ng, Efficient, long-term hepatic gene transfer using clinically relevant HDAd doses by balloon occlusion catheter delivery in nonhuman primates, Molecular therapy, J. Ameri- can Soci. Gene Ther. 17 (2) (2009) 327-333, doi:10.1038/mt.2008.257.

[144] I.H. Kim, A. Józkowicz, P.A. Piedra, K. Oka, L. Chan, Lifetime correction of genetic deficiency in mice with a single injection of helper-dependent ade- noviral vector, Proc. Natl. Acad. Sci. U.S.A. 98 (23) (2001) 13282-13287, doi:10.1073/pnas.241506298.

[145] K. Oka, L.M. Belalcazar, C. Dieker, E.A. Nour, P. Nuno-Gonzalez, A. Paul, S. Cormier, J.K. Shin, M. Finegold, L. Chan, Sustained phenotypic correction in a mouse model of hypoalphalipoproteinemia with a helper-dependent adenovirus vector, Gene Ther. 14 (3) (2007) 191-202, doi:10.1038/sj.gt.3302819.

[146] E. Leggiero, D. Astone, V. Cerullo, B. Lombardo, C. Mazzaccara, G. Labruna, L. Sac- chetti, F. Salvatore, M. Croyle, L. Pastore, PEGylated helper-dependent adenoviral vector expressing human Apo A-I for gene therapy in LDLR-deficient mice, Gene Ther. 20 (12) (2013) 1124-1130, doi:10.1038/gt.2013.38.

[147] B.K. Wacker, N. Dronadula, L. Bi, A. Stamatikos, D.A. Dichek, Apo A-I (Apolipopro- tein A-I) vascular gene therapy provides durable protection against atherosclerosis in hyperlipidemic rabbits, Arterioscler. Thromb. Vasc. Biol. 38 (1) (2018) 206-217, doi:10.1161/ATVBAHA.117.309565.

[148] L. Pastore, L.M. Belalcazar, K. Oka, R. Cela, B. Lee, L. Chan, A.L. Beaudet, Helper- dependent adenoviral vector-mediated long-term expression of human apolipopro- tein A-I reduces atherosclerosis in apo E-deficient mice, Gene 327 (2) (2004) 153-160, doi:10.1016/j.gene.2003.11.024.

[149] A. Stamatikos, N. Dronadula, P. Ng, D. Palmer, E. Knight, B.K. Wacker, C. Tang, F. Kim, D.A. Dichek, ABCA 1 overexpression in endothelial cells in vitro enhances ApoAI-mediated cholesterol efflux and decreases inflammation, Hum. Gene Ther. 30 (2) (2019) 236-248, doi:10.1089/hum.2018.120.

[150] L.A. Schwarz, K. Miyamichi, X.J. Gao, K.T. Beier, B. Weissbourd, K.E. DeLoach, J. Ren, S. Ibanes, R.C. Malenka, E.J. Kremer, L. Luo, Viral-genetic tracing of the input-output organization of a central noradrenaline circuit, Nature 524 (7563)(2015) 88-92, doi:10.1038/nature14600.

[151] C. Soudais, C. Laplace-Builhe, K. Kissa, E.J. Kremer, Preferential transduction of neurons by canine adenovirus vectors and their efficient retrograde transport in vivo, FASEB J. 15 (12) (2001) 2283-2285, doi:10.1096/fj.01-0321fje.

[152] L. Zou, H. Zhou, L. Pastore, K. Yang, Prolonged transgene expression mediated by a helper-dependent adenoviral vector (hdAd) in the central nervous system, Molecular therapy : the journal of the American Society of, Gene Ther. 2 (2) (2000) 105-113, doi:10.1006/mthe.2000.0104.

[153] V. Ridoux, J.J. Robert, X. Zhang, M. Perricaudet, J. Mallet, G. Le Gal Salle, Aden- oviral vectors as functional retrograde neuronal tracers, Brain Res. 648 (1) (1994) 171-175, doi:10.1016/0006-8993(94)91919-4.

[154] A. Kritzinger, B. Ferger, F. Gillardon, B. Stierstorfer, G. Birk, S. Kochanek, T. Ciossek, Age-related pathology after adenoviral overexpression of the leucine- rich repeat kinase 2 in the mouse striatum, Neurobiol. Aging 66 (2018) 97-111, doi:10.1016/j.neurobiolaging.2018.02.008.

[155] N. Mestre-Francés, N. Serratrice, A. Gennetier, G. Devau, S. Cobo, S.G. Trouche, P. Fontès, C. Zussy, P. de Deurwaerdere, S. Salinas, F.J. Mennechet, J. Dusonchet, B.L. Schneider, I. Saggio, V. Kalatzis, M.R. Luquin-Piudo, J.M. Verdier, E.J. Kremer, Exogenous LRRK2G2019S induces parkinsonian-like pathology in a nonhuman pri- mate, JCI insight 3 (14) (2018), doi:10.1172/jci.insight.98202.

[156] X. Dong, S. Zong, A. Witting, K.S. Lindenberg, S. Kochanek, B. Huang, Adenovirus vector-based in vitro neuronal cell model for Huntington’s disease with human disease-like differential aggregation and degeneration, J Gene Med 14 (7) (2012) 468-481, doi:10.1002/jgm.2641.

[157] L.R. Gooding, T.S. Ranheim, A.E. Tollefson, L. Aquino, P. Duerksen-Hughes, T. M. Horton, W.S. Wold, The 10,400- and 14,500-dalton proteins encoded by re- gion E3 of adenovirus function together to protect many but not all mouse cell lines against lysis by tumor necrosis factor, J. Virol. 65 (8) (1991) 4114-4123, doi:10.1128/JVI.65.8.4114-4123.1991.

[158] M. Ishizaki, Y. Maeda, R. Kawano, T. Suga, Y. Uchida, K. Uchino, S. Ya- mashita, E. Kimura, M. Uchino, Rescue from respiratory dysfunction by trans- duction of full-length dystrophin to diaphragm via the peritoneal cavity in utrophin/dystrophin double knockout mice, Mol. Ther. 19 (7) (2011) 1230-1235, doi:10.1038/mt.2011.58.

[159] K. Guse, M. Suzuki, G. Sule, T.K. Bertin, H. Tyynismaa, S. Ahola-Erkkilä, D. Palmer, A. Suomalainen, P. Ng, V. Cerullo, A. Hemminki, B. Lee, Capsid-modified adenovi- ral vectors for improved muscle-directed gene therapy, Hum. Gene Ther. 23 (10) (2012) 1065-1070, doi:10.1089/hum.2012.003.

[160] A. Ricobaraza, M. Gonzalez-Aparicio, L. Mora-Jimenez, S. Lumbreras, R. Hernandez-Alcoceba,High-capacity adenoviral vectors: expanding the scope of gene therapy, Int J Mol Sci 21 (10) (2020), doi:10.3390/ijms21103643.

[161] M. Richter, K. Saydaminova, R. Yumul, R. Krishnan, J. Liu, E.E. Nagy, M. Singh, Z. Izsvák, R. Cattaneo, W. Uckert, D. Palmer, P. Ng, K.G. Haworth, H.P. Kiem, A. Ehrhardt, T. Papayannopoulou, A. Lieber, In vivo transduction of primitive mobi- lized hematopoietic stem cells after intravenous injection of integrating adenovirus vectors, Blood 128 (18) (2016) 2206-2217, doi:10.1182/blood-2016-04-711580.

[162] H. Wang, A. Georgakopoulou, W. Zhang, J. Kim, S. Gil, A. Ehrhardt, A. Lieber, HDAd6/ 35 ++ - A new helper-dependent adenovirus vector platform for in vivo transduction of hematopoietic stem cells, Molecular therapy, Methods clinical de- velop. 29(2023) 213-226, doi:10.1016/j.omtm.2023.03.008.

[163] H. Wang, A. Germond, C. Li, S. Gil, J. Kim, H.P. Kiem, A. Lieber, In vivo HSC transduction in rhesus macaques with an HDAd5/3 + vector targeting desmoglein 2 and transiently overexpressing cxcr4, Blood adv. 6 (15) (2022) 4360-4372, doi:10.1182/bloodadvances.2022007975.

[164] G. Schiedner, N. Morral, R.J. Parks, Y. Wu, S.C. Koopmans, C. Langston, F.L. Gra- ham, A.L. Beaudet, S. Kochanek, Genomic DNA transfer with a high-capacity ade- novirus vector results in improved in vivo gene expression and decreased toxicity, Nat. Genet. 18 (2) (1998) 180-183, doi:10.1038/ng0298-180.

[165] W.K. O’Neal, H. Zhou, N. Morral, C. Langston, R.J. Parks, F.L. Graham, S. Kochanek, A. L. Beaudet, Toxicity associated with repeated administration of first-generation adenovirus vectors does not occur with a helper-dependent vector, Mol. Med. 6 (3)(2000) 179-195.

[166] B.D. Brown, C.X. Shi, S. Powell, D. Hurlbut, F.L. Graham, D. Lillicrap, Helper- dependent adenoviral vectors mediate therapeutic factor VIII expression for sev- eral months with minimal accompanying toxicity in a canine model of severe hemophilia A, Blood 103 (3) (2004) 804-810, doi:10.1182/blood-2003-05-1426.

[167] S.E. Raper, N. Chirmule, F.S. Lee, N.A. Wivel, A. Bagg, G.P. Gao, J.M. Wilson, M. L. Batshaw, Fatal systemic inflammatory response syndrome in a ornithine tran- scarbamylase deficient patient following adenoviral gene transfer, Mol. Genet. Metab. 80 (1-2) (2003) 148-158, doi:10.1016/j.ymgme.2003.08.016.

[168] N. Brunetti-Pierri, T. Ng, D.A. Iannitti, D.J. Palmer, A.L. Beaudet, M.J. Finegold, K. D. Carey, W.G Cioffi, P. Ng, Improved hepatic transduction, reduced systemic vector dissemination, and long-term transgene expression by delivering helper- dependent adenoviral vectors into the surgically isolated liver of nonhuman pri- mates, Hum. Gene Ther. 17 (4) (2006) 391-404, doi:10.1089/hum.2006.17.391.

[169] A. Kiang, Z.C. Hartman, S. Liao, F. Xu, D. Serra, D.J. Palmer, P. Ng, A. Amal- fitano, Fully deleted adenovirus persistently expressing GAA accomplishes long- term skeletal muscle glycogen correction in tolerant and nontolerant GSD-II mice, Molecular therapy, J. American Soc. Gene Ther. 13 (1) (2006) 127-134, doi:10.1016/j.ymthe.2005.08.006.

[170] R. Kawano, M. Ishizaki, Y. Maeda, Y. Uchida, E. Kimura, M. Uchino, Transduction of full-length dystrophin to multiple skeletal muscles improves motor performance and life span in utrophin/dystrophin double knockout mice, Molecular therapy, J. American Soc. Gene Ther. 16 (5) (2008) 825-831, doi:10.1038/mt.2008.23.

[171] L.M. Belalcazar, A. Merched, B. Carr, K. Oka, K.H. Chen, L. Pastore, A. Beaudet, L. Chan, Long-term stable expression of human apolipoprotein A- I mediated by helper-dependent adenovirus gene transfer inhibits atheroscle- rosis progression and remodels atherosclerotic plaques in a mouse model of familial hypercholesterolemia, Circulation 107 (21) (2003) 2726-2732, doi:10.1161/01.CIR.0000066913.69844.B2.

[172] C. Unzu, A. Sampedro, I. Mauleón, M. González-Aparicio, R. Enríquez de Sala- manca, J. Prieto, T. Aragón, A. Fontanellas, Helper-dependent adenoviral liver gene therapy protects against induced attacks and corrects protein folding stress in acute intermittent porphyria mice, Hum. Mol. Genet. 22 (14) (2013) 2929-2940, doi:10.1093/hmg/ddt148.

[173] L. Ariza, L. Giménez-Llort, A. Cubizolle, G. Pagès, B. García-Lareu, N. Serratrice, D. Cots, R. Thwaite, M. Chillón, E.J. Kremer, A. Bosch, Central nervous system delivery of helper-dependent canine adenovirus corrects neuropathology and be- havior in mucopolysaccharidosis type VII mice, Hum. Gene Ther. 25 (3) (2014) 199-211, doi:10.1089/hum.2013.152.

[174] R. Castello, R. Borzone, S. D’Aria, P. Annunziata, P. Piccolo, N. Brunetti-Pierri, Helper-dependent adenoviral vectors for liver-directed gene therapy of primary hy- peroxaluria type 1, Gene Ther. 23 (2) (2016) 129-134, doi:10.1038/gt.2015.107.

[175] H. Cao, H. Ouyang, H. Grasemann, C. Bartlett, K. Du, R. Duan, F. Shi, M. Estrada, K.E. Seigel, A.L. Coates, H. Yeger, C.E. Bear, T. Gonska, T.J. Moraes, J. Hu, Trans- ducing airway basal cells with a helper-dependent adenoviral vector for lung gene therapy, Hum. Gene Ther. 29 (6) (2018) 643-652, doi:10.1089/hum.2017.201.

[176] G. Toietta, D.R. Koehler, M.J. Finegold, B. Lee, J. Hu, A.L. Beaudet, Reduced inflammation and improved airway expression using helper-dependent aden- oviral vectors with a K18 promoter, Mol. Ther. 7 (5 Pt 1) (2003) 649-658, doi:10.1016/s1525-0016(03)00059-5.

[177] P. Ng, R.J. Parks, F.L. Graham, Preparation of helper-dependent adenoviral vectors, Methods Mol. Med. 69 (2002) 371-388, doi:10.1385/1-59259-141-8:371.

[178] D. Palmer, P. Ng, Improved system for helper-dependent adenoviral vector produc- tion, Molecular therapy : the journal of the American Society of, Gene Ther. 8 (5)(2003) 846-852, doi:10.1016/j.ymthe.2003.08.014.

[179] H. Wang, A. Georgakopoulou, W. Zhang, J. Kim, S. Gil, A. Ehrhardt, A. Lieber, HDAd6/ 35 ++ - A new helper-dependent adenovirus vector platform for in vivo transduction of hematopoietic stem cells, Molecular therapy, Methods & clinical develop. 29(2023) 213-226, doi:10.1016/j.omtm.2023.03.008.

[180] P. Blanchette, J.G. Teodoro, A renaissance for oncolytic adenoviruses? Viruses 15 (2) (2023), doi:10.3390/v15020358.

[181] Y. Zhao, Z. Liu, L. Li, J. Wu, H. Zhang, H. Zhang, T. Lei, B. Xu, Oncolytic aden- ovirus: prospects for cancer immunotherapy, Front Microbiol 12 (2021) 707290, doi:10.3389/fmicb.2021.707290.

[182] P.B. Hajeri, N.S. Sharma, M. Yamamoto, Oncolytic adenoviruses: strategies for im- proved targeting and specificity, Cancers (Basel) 12 (6) (2020), doi:10.3390/can- cers12061504.

[183] B. Oronsky, B. Gastman, A.P. Conley, C. Reid, S. Caroen, T. Reid, Oncolytic ade- noviruses: the cold war against cancer finally turns hot, Cancers (Basel) 14 (19)(2022), doi:10.3390/cancers14194701.

[184] S.Z. Shalhout, D.M. Miller, K.S. Emerick, H.L. Kaufman, Therapy with oncolytic viruses: progress and challenges, Nat Rev Clin Oncol 20 (3) (2023) 160-177, doi:10.1038/s41571-022-00719-w.

[185] V.N. Krasnykh, G.V. Mikheeva, J.T. Douglas, D.T. Curiel, Generation of recombi- nant adenovirus vectors with modified fibers for altering viral tropism, J. Virol. 70 (10) (1996) 6839-6846, doi:10.1128/JVI.70.10.6839-6846.1996.

[186] W. Chen, Y. Wu, W. Liu, G. Wang, X. Wang, Y. Yang, W. Chen, Y. Tai, M. Lu, Q. Qian, Q. Zhang, G. Chen, Enhanced antitumor efficacy of a novel fiber chimeric oncolytic adenovirus expressing p53 on hepatocellular carcinoma, Cancer Lett. 307 (1) (2011) 93-103, doi:10.1016/j.canlet.2011.03.021.

[187] B. Wang, J. Liu, L.N. Ma, H.L. Xiao, Y.Z. Wang, Y. Li, Z. Wang, L. Fan, C. Lan, M. Yang, L. Hu, Y. Wei, X.W. Bian, D. Chen, J. Wang, Chimeric 5/35 adenovirus- mediated Dickkopf-1 overexpression suppressed tumorigenicity of CD44+ gastric cancer cells via attenuating Wnt signaling, J. Gastroenterol. 48 (7) (2013) 798-808, doi:10.1007/s00535-012-0711-z.

[188] M.H. Do, P.K. To, Y.S. Cho, S.Y. Kwon, E.C. Hwang, C. Choi, S.H. Cho, S.J. Lee, S. Hemmi, C. Jung, Targeting CD46 enhances anti-tumoral activity of adenovirus Type 5 for bladder cancer, Int J Mol Sci 19 (9) (2018), doi:10.3390/ijms19092694.

[189] G.J. Bauerschmitz, K. Guse, A. Kanerva, A. Menzel, I. Herrmann, R.A. Desmond, M. Yamamoto, D.M. Nettelbeck, T. Hakkarainen, P. Dall, D.T. Curiel, A. Hemminki, Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcom- plementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells, Molecular therapy : the journal of the American Society of, Gene Ther. 14 (2)(2006) 164-174, doi:10.1016/j.ymthe.2006.01.010.

[190] J. Gao, W. Zhang, K. Mese, O. Bunz, F. Lu, A. Ehrhardt, Transient chimeric Ad5/37 fiber enhances NK-92 carrier cell-mediated delivery of oncolytic adenovirus type 5 to tumor cells, molecular therapy, Methods clinical develop. 18 (2020) 376-389, doi:10.1016/j.omtm.2020.06.010.

[191] I. Kuhn, P. Harden, M. Bauzon, C. Chartier, J. Nye, S. Thorne, T. Reid, S. Ni, A. Lieber, K. Fisher, L. Seymour, G.M. Rubanyi, R.N. Harkins, T.W. Hermiston, Directed evolution generates a novel oncolytic virus for the treatment of colon cancer, PLoS ONE 3 (6) (2008) e2409, doi:10.1371/journal.pone.0002409.

[192] J.P. Machiels, R. Salazar, S. Rottey, I. Duran, L. Dirix, K. Geboes, C. Wilkinson-Blanc, G. Pover, S. Alvis, B. Champion, K. Fisher, H. McElwaine-Johnn, J. Beadle, E. Calvo, A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with ep- ithelial solid tumors (EVOLVE), J Immunother Cancer 7 (1) (2019) 20, doi:10.1186/s40425-019-0510-7.

[193] I. Kuhn, M. Bauzon, N. Green, L. Seymour, K. Fisher, T. Hermiston, OvAd1, a Novel, potent, and selective chimeric oncolytic virus developed for ovar- ian cancer by 3D-directed evolution, Mol Ther Oncolytics 4 (2017) 55-66, doi:10.1016/j.omto.2016.12.001.

[194] O. Hemminki, G. Bauerschmitz, S. Hemmi, S. Lavilla-Alonso, I. Diaconu, K. Guse, A. Koski, R.A. Desmond, M. Lappalainen, A. Kanerva, V. Cerullo, S. Pesonen, A. Hemminki, Oncolytic adenovirus based on serotype 3, Cancer Gene Ther. 18 (4) (2011) 288-296, doi:10.1038/cgt.2010.79.

[195] J. Chang, X. Zhao, X. Wu, Y. Guo, H. Guo, J. Cao, Y. Guo, D. Lou, D. Yu, J. Li, A Phase I study of KH901, a conditionally replicating granulocyte- macrophage colony-stimulating factor: armed oncolytic adenovirus for the treat- ment of head and neck cancers, Cancer Biol. Ther. 8 (8) (2009) 676-682, doi:10.4161/cbt.8.8.7913.

[196] R. Ono, K. Takayama, F. Sakurai, H. Mizuguchi, Efficient antitumor effects of a novel oncolytic adenovirus fully composed of species B adenovirus serotype 35, Mol Ther Oncolytics 20 (2021) 399-409, doi:10.1016/j.omto.2021.01.015.

[197] S. Zafar, S. Parviainen, M. Siurala, O. Hemminki, R. Havunen, S. Tähtinen, S. Bra- mante, L. Vassilev, H. Wang, A. Lieber, S. Hemmi, T. de Gruijl, A. Kanerva, A. Hem- minki, Intravenously usable fully serotype 3 oncolytic adenovirus coding for CD40L as an enabler of dendritic cell therapy, Oncoimmunology 6 (2) (2017) e1265717, doi:10.1080/2162402X.2016.1265717.

[198] X. Wang, C. Su, H. Cao, K. Li, J. Chen, L. Jiang, Q. Zhang, X. Wu, X. Jia, Y. Liu, W. Wang, X. Liu, M. Wu, Q. Qian, A novel triple-regulated oncolytic adenovirus car- rying p53 gene exerts potent antitumor efficacy on common human solid cancers, Mol. Cancer Ther. 7 (6) (2008) 1598-1603, doi:10.1158/1535-7163.MCT-07-2429.

[199] I.D. Osipov, V.A. Vasikhovskaia, D.S. Zabelina, S.S. Kutseikin, A.A. Grazhdantseva, G. V. Kochneva, J. Davydova, S.V. Netesov, M.V. Romanenko, Development of on- colytic vectors based on human adenovirus Type 6 for cancer treatment, Viruses 15 (1) (2023), doi:10.3390/v15010182.

[200] O. Hemminki, S. Parviainen, J. Juhila, R. Turkki, N. Linder, J. Lundin, M. Kankainen, A. Ristimäki, A. Koski, I. Liikanen, M. Oksanen, D.M. Nettelbeck, K. Kairemo, K. Partanen, T. Joensuu, A. Kanerva, A. Hemminki, Immunological data from cancer patients treated with Ad5/3-E2F- Δ24-GMCSF suggests utility for tumor immunotherapy, Oncotarget 6 (6) (2015) 4467-4481, doi:10.18632/onco-target.2901.

[201] N. Ramesh, Y. Ge, D.L. Ennist, M. Zhu, M. Mina, S. Ganesh, P.S. Reddy, D.C. Yu, CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor-armed oncolytic adenovirus for the treatment of bladder cancer, Clin. Cancer Res. 12 (1) (2006) 305-313, doi:10.1158/1078-0432.CCR-05-1059.

[202] L. Johnson, A. Shen, L. Boyle, J. Kunich, K. Pandey, M. Lemmon, T. Hermiston, M. Giedlin, F. McCormick, A. Fattaey, Selectively replicating adenoviruses target- ing deregulated E2F activity are potent, systemic antitumor agents, Cancer Cell 1 (4) (2002) 325-337, doi:10.1016/s1535-6108(02)00060-0.

[203] P.L. Hallenbeck, Y.N. Chang, C. Hay, D. Golightly, D. Stewart, J. Lin, S. Phipps, Y. L. Chiang, A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma, Hum. Gene Ther. 10 (10) (1999) 1721-1733, doi:10.1089/10430349950017725.

[204] J. Kim, B. Lee, J.S. Kim, C.O. Yun, J.H. Kim, Y.J. Lee, C.H. Joo, H. Lee, Antitumoral effects of recombinant adenovirus YKL-1001, conditionally replicating in alpha- fetoprotein-producing human liver cancer cells, Cancer Lett. 180 (1)(2002) 23-32, doi:10.1016/s0304-3835(02)00017-4.

[205] R. Rodriguez, E.R. Schuur, H.Y. Lim, G.A. Henderson, J.W. Simons, D.R. Henderson, Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells, Cancer Res. 57 (13) (1997) 2559-2563.

[206] D.C. Yu, Y. Chen, M. Seng, J. Dilley, D.R. Henderson, The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts, Cancer Res. 59 (17) (1999) 4200-4203.

[207] D.C. Yu, G.T. Sakamoto, D.R. Henderson, Identification of the transcriptional regu- latory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer ther- apy, Cancer Res. 59 (7) (1999) 1498-1504.

[208] T. Kurihara, D.E. Brough, I. Kovesdi, D.W. Kufe, Selectivity of a replication- competent adenovirus for human breast carcinoma cells expressing the MUC1 anti- gen, J. Clin. Invest. 106 (6) (2000) 763-771, doi:10.1172/JCI9180.

[209] C. Liu, B. Sun, N. An, W. Tan, L. Cao, X. Luo, Y. Yu, F. Feng, B. Li, M. Wu, C. Su, X. Jiang, Inhibitory effect of Survivin promoter-regulated oncolytic adenovirus carrying P53 gene against gallbladder cancer, Mol Oncol 5 (6) (2011) 545-554, doi:10.1016/j.molonc.2011.10.001.

[210] J. Fueyo, C. Gomez-Manzano, R. Alemany, P.S. Lee, T.J. McDonnell, P. Mitlianga, Y. X. Shi, V.A. Levin, W.K. Yung, A.P. Kyritsis, A mutant oncolytic adenovirus tar- geting the Rb pathway produces anti-glioma effect in vivo, Oncogene 19 (1) (2000) 2-12, doi:10.1038/sj.onc.1203251.

[211] W. Dong, J.-W.H. van Ginkel, K.Y. Au, R. Alemany, J.J.M. Meulenberg, V.W. van Beusechem, ORCA-010, a novel potency-enhanced oncolytic adenovirus, exerts strong antitumor activity in preclinical models, Hum. Gene Ther. 25 (10) (2014) 897-904, doi:10.1089/hum.2013.229.

[212] D. Oberg, E. Yanover, V. Adam, K. Sweeney, C. Costas, N.R. Lemoine, G. Halldén, Improved potency and selectivity of an oncolytic E1ACR2 and E1B19K deleted adenoviral mutant in prostate and pancreatic cancers, Clinical cancer research : an official journal of the American Association for, Cancer Res. 16 (2) (2010) 541-553, doi:10.1158/1078-0432.CCR-09-1960.

[213] J. Fueyo, R. Alemany, C. Gomez-Manzano, G.N. Fuller, A. Khan, C.A. Conrad, T.J. Liu, H. Jiang, M.G. Lemoine, K. Suzuki, R. Sawaya, D.T. Curiel, W.K.A. Yung, F.F. Lang, Preclinical characterization of the antiglioma activity of a tropism- enhanced adenovirus targeted to the retinoblastoma pathway, J. Natl. Cancer Inst. 95 (9) (2003) 652-660, doi:10.1093/jnci/95.9.652.

[214] C. Heise, T. Hermiston, L. Johnson, G. Brooks, A. Sampson-Johannes, A. Williams, L. Hawkins, D. Kirn, An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy, Nat. Med. 6 (10) (2000) 1134-1139, doi:10.1038/80474.

[215] K. Doronin, K. Toth, M. Kuppuswamy, P. Ward, A.E. Tollefson, W.S. Wold, Tumor-specific, replication-competent adenovirus vectors overexpress- ing the adenovirus death protein, J. Virol. 74 (13) (2000) 6147-6155, doi:10.1128/jvi.74.13.6147-6155.2000.

[216] D.D. Barker, A.J. Berk, Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection, Virology 156 (1) (1987) 107-121, doi:10.1016/0042-6822(87) 90441-7.

[217] T. Subramanian, M. Kuppuswamy, S. Mak, G. Chinnadurai, Adenovirus cyt + locus, which controls cell transformation and tumorigenicity, is an allele of lp + locus, which codes for a 19-kilodalton tumor antigen, J. Virol. 52 (2) (1984) 336-343, doi:10.1128/JVI.52.2.336-343.1984.

[218] N. Jones, T. Shenk, Isolation of adenovirus type 5 host range deletion mutants defective for transformation of rat embryo cells, Cell 17 (3) (1979) 683-689, doi:10.1016/0092-8674(79)90275-7.

[219] Y. Wang, G. Hallden, R. Hill, A. Anand, T.C. Liu, J. Francis, G. Brooks, N. Lemoine, D. Kirn, E 3 gene manipulations affect oncolytic adenovirus activity in im- munocompetent tumor models, Nat. Biotechnol. 21 (11) (2003) 1328-1335, doi:10.1038/nbt887.

[220] A. Krishan, Cellular resistance to drugs, Cancer Invest. 7 (2) (1989) 211-212, doi:10.3109/07357908909038287.

[221] N. Lei, F.B. Shen, J.H. Chang, L. Wang, H. Li, C. Yang, J. Li, D.C. Yu, An oncolytic adenovirus expressing granulocyte macrophage colony-stimulating factor shows improved specificity and efficacy for treating human solid tumors, Cancer Gene Ther. 16 (1) (2009) 33-43, doi:10.1038/cgt.2008.46.

[222] S. Zafar, S. Basnet, I.M. Launonen, D.C.A. Quixabeira, J. Santos, O. Hemminki, M. Malmstedt, V. Cervera-Carrascon, P. Aronen, R. Kalliokoski, R. Havunen, A. Ran- nikko, T. Mirtti, M. Matikainen, A. Kanerva, A. Hemminki, Oncolytic adenovirus type 3 coding for cd40l facilitates dendritic cell therapy of prostate cancer in hu- manized mice and patient samples, Hum. Gene Ther. 32 (3-4) (2021) 192-202, doi:10.1089/hum.2020.222.

[223] S. Zafar, S. Sorsa, M. Siurala, O. Hemminki, R. Havunen, V. Cervera-Carrascon, J. M. Santos, H. Wang, A. Lieber, T. de Gruijl, A. Kanerva, A. Hemminki, CD40L coding oncolytic adenovirus allows long-term survival of humanized mice receiving dendritic cell therapy, Oncoimmunology 7 (10) (2018) e1490856, doi:10.1080/2162402X.2018.1490856.

[224] M. Ramachandra, A. Rahman, A. Zou, M. Vaillancourt, J.A. Howe, D. Antelman, B. Sugarman, G.W. Demers, H. Engler, D. Johnson, P. Shabram, Re -engineering adenovirus regulatory pathways to enhance oncolytic specificity and efficacy, Nat. Biotechnol. 19 (11) (2001) 1035-1041, doi:10.1038/nbt1101-1035.

[225] S. Zafar, D.C.A. Quixabeira, T.V. Kudling, V. Cervera-Carrascon, J.M. Santos, S. Grönberg-Vähä-Koskela, F. Zhao, P. Aronen, C. Heiniö, R. Havunen, S. Sorsa, A. Kanerva, A. Hemminki, Ad5/ 3 is able to avoid neutralization by binding to erythrocytes and lymphocytes, Cancer Gene Ther. 28 (5) (2021) 442-454, doi:10.1038/s41417-020-00226-z.

[226] L. Koodie, M.G. Robertson, M. Chandrashekar, G. Ruth, M. Dunning, R.W. Bianco, J. Davydova, Rodents versus pig model for assessing the performance of serotype chimeric Ad5/3 oncolytic adenoviruses, Cancers (Basel) 11 (2) (2019), doi:10.3390/cancers11020198.

[227] O. Hemminki, I. Diaconu, V. Cerullo, S.K. Pesonen, A. Kanerva, T. Joensuu, K. Kairemo, L. Laasonen, K. Partanen, L. Kangasniemi, A. Lieber, S. Pesonen, A. Hemminki, Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in pa- tients with chemotherapy refractory cancer, Mol. Ther. 20 (9) (2012) 1821-1830, doi:10.1038/mt.2012.115.

[228] F. Shen, J. Chang, C. Yang, J. Li, Y. Guo, B. Yi, H. Li, X. Ye, L. Wang, Tumor-se- lective replication, cytotoxicity and GM-CSF production of oncolytic recombinant adenovirus in KH901 injection, Sichuan Da Xue Xue Bao Yi Xue Ban 38 (1) (2007) 31-34.

[229] R. Ono, K. Takayama, R. Onishi, S. Tokuoka, F. Sakurai, H. Mizuguchi, Treatment of human pancreatic cancers following local and systemic administration of oncolytic adenovirus serotype 35, Anticancer Res. 43 (2) (2023) 537-546, doi:10.21873/an-ticanres.16190.

[230] R. Li, G.D. Steinberg, E.M. Uchio, D.L. Lamm, P. Shah, A.M. Kamat, T. Bivalac- qua, V.T. Packiam, M.J. Chisamore, J. McAdory, P. Grandi, N. Hnat, J. Burke, CORE1: phase 2, single-arm study of CG0070 combined with pembrolizumab in patients with nonmuscle-invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guerin (BCG), J. Clinical Oncology 40 (16_suppl) (2022) 4597, doi:10.1200/JCO.2022.40.16_suppl.4597.

[231] T.L. DeWeese, H. van der Poel, S. Li, B. Mikhak, R. Drew, M. Goemann, U. Ham- per, R. DeJong, N. Detorie, R. Rodriguez, T. Haulk, A.M. DeMarzo, S. Piantadosi, D. C. Yu, Y. Chen, D.R. Henderson, M.A. Carducci, W.G. Nelson, J.W. Simons, A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy, Cancer Res. 61 (20) (2001) 7464-7472.

[232] E.J. Small, M.A. Carducci, J.M. Burke, R. Rodriguez, L. Fong, L. van Ummersen, D. C. Yu, J. Aimi, D. Ando, P. Working, D. Kirn, G. Wilding, A phase I trial of in- travenous CG (1) (7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer, Mol. Ther. 14 (1) (2006) 107-117, doi:10.1016/j.ymthe.2006.02.011.

[233] D. Kirn, Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned? Gene Ther. 8 (2)(2001) 89-98, doi:10.1038/sj.gt.3301377.

[234] J. Nemunaitis, I. Ganly, F. Khuri, J. Arseneau, J. Kuhn, T. McCarty, S. Landers, P. Maples, L. Romel, B. Randlev, T. Reid, S. Kaye, D. Kirn, Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial, Cancer Res. 60 (22) (2000) 6359-6366.

[235] I. Ganly, D. Kirn, G. Eckhardt, G.I. Rodriguez, D.S. Soutar, R. Otto, A.G. Robert- son, O. Park, M.L. Gulley, C. Heise, D.D. von Hoff, S.B. Kaye, A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer, Clin. Cancer Res. 6 (3) (2000) 798-806.

[236] D. Kirn, T. Hermiston, F. McCormick, ONYX-015: clinical data are encouraging, Nat. Med. 4 (12) (1998) 1341-1342, doi:10.1038/3902.

[237] C. Heise, A. Sampson-Johannes, A. Williams, F. McCormick, D.D. von Hoff, D. H. Kirn, ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemother- apeutic agents, Nat. Med. 3 (6) (1997) 639-645, doi:10.1038/nm0697-639.

[238] J.R. Bischoff, D.H. Kirn, A. Williams, C. Heise, S. Horn, M. Muna, L. Ng, J.A. Nye, A. Sampson-Johannes, A. Fattaey, F. McCormick, An adenovirus mutant that repli- cates selectively in p53-deficient human tumor cells, Science 274 (5286) (1996) 373-376, doi:10.1126/science.274.5286.373.

[239] T.C. Liu, G. Hallden, Y. Wang, G. Brooks, J. Francis, N. Lemoine, D. Kirn, An E1B-19kDa gene deletion mutant adenovirus demonstrates tumor necrosis factor- enhanced cancer selectivity and enhanced oncolytic potency, Molecular therapy : the journal of the American Society of, Gene Ther. 9 (6) (2004) 786-803, doi:10.1016/j.ymthe.2004.03.017.

[240] P. Whyte, N.M. Williamson, E. Harlow, Cellular targets for transfor- mation by the adenovirus E1A proteins, Cell 56 (1) (1989) 67-75, doi:10.1016/0092-8674(89)90984-7.

[241] S.O. Freytag, K.R. Rogulski, D.L. Paielli, J.D. Gilbert, J.H. Kim, A novel three- pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy, Hum. Gene Ther. 9 (9) (1998) 1323-1333, doi:10.1089/hum.1998.9.9-1323.

[242] F.F. Lang, C. Conrad, C. Gomez-Manzano, W.K.A. Yung, R. Sawaya, J.S. Wein- berg, S.S. Prabhu, G. Rao, G.N. Fuller, K.D. Aldape, J. Gumin, L.M. Vence, I. Wis- tuba, J. Rodriguez-Canales, P.A. Villalobos, C.M.F. Dirven, S. Tejada, R.D. Valle, M. M. Alonso, B. Ewald, J.J. Peterkin, F. Tufaro, J. Fueyo, Phase I Study of DNX- 2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic ef- fects in recurrent malignant glioma, J. Clinical Oncology 36 (14) (2018) 1419-1427, doi:10.1200/JCO.2017.75.8219.